Top

Published in:

01-04-2018 | Original Paper

Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis

Authors: Sonia C. DaSilva-Arnold, Anita Thyagarajan, Leroy J. Seymour, Qiaofang Yi, Joshua R. Bradish, Mohammed Al-Hassani, Hongming Zhou, Nikolajs J. Perdue, Val Nemeth, Aleksandar Krbanjevic, Ana P. M. Serezani, Matthew R. Olson, Dan F. Spandau, Jeffrey B. Travers, Mark H. Kaplan, Matthew J. Turner

Published in: Archives of Dermatological Research | Issue 3/2018

Abstract

The Stat6VT mouse model of atopic dermatitis (AD) is induced by T-cell-specific expression of a constitutively active form of the protein signal transducer and activator of transcription 6 (STAT6). Although AD-like lesions are known to develop in Stat6VT mice, this study was designed to determine if these mice develop acute and chronic phases of disease similar to humans. To address this, AD-like lesions from Stat6VT mice were harvested at two different timepoints relative to their onset. Lesions harvested within 1 week after development were defined as acute lesions, and those present for 1 month or more were defined as chronic lesions. Acute and chronic AD-like lesions from Stat6VT mice exhibited histologic findings and cytokine expression patterns similar to acute and chronic AD lesions in humans. Further analysis revealed increased levels of interleukin (IL)-33 transcripts in AD-like lesions compared to Stat6VT nonlesional and wild-type skin controls. Immunofluorescence also revealed increased numbers of IL-33⁺ keratinocytes in Stat6VT lesional skin and localized IL-33⁺ keratinocytes to a keratin 5⁺ subset. Furthermore, AD-like disease was more severe in IL-33-deficient Stat6VT mice compared to IL-33-sufficient Stat6VT mice. These studies suggest that Stat6VT mice can serve as a model of acute and chronic AD and that IL-33 may attenuate inflammation in this system.

Ali S et al (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 104:18660–18665CrossRefPubMedPubMedCentral

Ali S et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616CrossRefPubMed

Arpaia N et al (2015) A distinct function of regulatory T Cells in tissue protection. Cell 162:1078–1089CrossRefPubMedPubMedCentral

Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139CrossRefPubMed

Bieber T (2008) Atopic dermatitis. N Engl J Med 358:1483–1494CrossRefPubMed

Brunner SM et al (2011) Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 24:1027–1039CrossRefPubMed

Bruns HA et al (2003) Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 170:3478–3487CrossRefPubMed

Carriere V et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104:282–287CrossRefPubMed

Chackerian AA et al (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555CrossRefPubMed

10.

Choi YS et al (2012) Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 421:305–311CrossRefPubMed

11.

Daniel C et al (2000) A gain-of-function mutation in STAT6. J Biol Chem 275:14255–14259CrossRefPubMed

12.

DaSilva SC et al (2012) Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res 304:65–71CrossRefPubMed

13.

Dillon SR et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760CrossRefPubMed

14.

Duan L et al (2012) Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 18:753–761CrossRefPubMedPubMedCentral

15.

Ewald DA et al (2017) Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol 139:562–571CrossRefPubMed

16.

Gajardo T et al (2015) Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3(+) regulatory T cells in skin-transplanted mice. Immunology 146:81–88CrossRefPubMedPubMedCentral

17.

Gandhi NA et al (2016) Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15:35–50CrossRefPubMed

18.

Griesenauer B, Paczesny S (2017) The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol 8:475CrossRefPubMedPubMedCentral

19.

Hanifin JM et al (2001) The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10:11–18CrossRef

20.

Imai Y et al (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110:13921–13926CrossRefPubMedPubMedCentral

21.

Jiang HR et al (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 42:1804–1814CrossRefPubMed

22.

Kakkar R et al (2012) Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 287:6941–6948CrossRefPubMedPubMedCentral

23.

Kim BS et al (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra116CrossRef

24.

Kouzaki H et al (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375–4387CrossRefPubMedPubMedCentral

25.

Li M et al (2006) Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 103:11736–11741CrossRefPubMedPubMedCentral

26.

Liew FY et al (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16:676–689CrossRefPubMed

27.

Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461–466CrossRefPubMed

28.

Matta BM et al (2014) IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J Immunol 193:4010–4020CrossRefPubMedPubMedCentral

29.

Matta BM et al (2016) Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 128:427–439CrossRefPubMedPubMedCentral

30.

Monticelli LA et al (2015) IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112:10762–10767CrossRefPubMedPubMedCentral

31.

Moussion C et al. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PloS One. 3, e3331

32.

Noel G et al (2016) Ablation of interaction between IL-33 and ST2 + regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration. Am J Physiol Gastrointest Liver Physiol 311:G313–G323CrossRefPubMed

33.

Oshio T et al (2017) Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci 85:106–114CrossRefPubMed

34.

Oyoshi MK et al (2016) Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis. J Allergy Clin Immunol 138:283–286CrossRefPubMedPubMedCentral

35.

Peine M et al (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333CrossRefPubMed

36.

Popovic B et al. (2017) IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 13, e1006345

37.

Rak GD et al (2016) IL-33-Dependent Group 2 innate lymphoid cells promote cutaneous wound healing. J Invest Dermatol 136:487–496CrossRefPubMedPubMedCentral

38.

Ryu WI et al (2016) IL-33 down-regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes. J Dermatol Sci 82:131–134CrossRefPubMed

39.

Salimi M et al (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210:2939–2950CrossRefPubMedPubMedCentral

40.

Savinko T et al (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Investig Dermatol 133:2522–2529CrossRefPubMed

41.

Schiering C et al (2014) The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513:564–568CrossRefPubMedPubMedCentral

42.

Schmitz J et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMed

43.

Sehra S et al (2008) IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6. J Immunol 180:3551–3559CrossRefPubMed

44.

Sehra S et al (2010) IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 184:3186–3190CrossRefPubMedPubMedCentral

45.

Sehra S et al (2016) Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. Eur J Immunol 46:2609–2613CrossRefPubMedPubMedCentral

46.

Seltmann J et al (2015) IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135:1659–1661.e4CrossRefPubMed

47.

Serezani AP et al (2017) IL-4 impairs wound healing potential in the skin by repressing fibronectin expression. J Allergy Clin Immunol 139:142–151.e5CrossRefPubMed

48.

Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673–680CrossRefPubMed

49.

Souwer Y et al (2010) IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 22:821–826CrossRefPubMed

50.

Turner MJ et al (2012) T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol 11:1174–1178PubMed

51.

Turner MJ et al (2013) Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice. Pediatr Dermatol 30:574–578CrossRefPubMedPubMedCentral

52.

Turner MJ et al (2014) STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis. Investig Ophthalmol Vis Sci 55:3803–3808CrossRef

53.

Turnquist HR et al (2011) IL-33 expands suppressive CD11b + Gr-1(int) and regulatory T cells, including ST2L + Foxp3 + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 187:4598–4610CrossRefPubMedPubMedCentral

54.

Vasanthakumar A et al (2015) The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 16:276–285CrossRefPubMed

55.

Yin H et al (2013) IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol 56:347–353CrossRefPubMed

56.

Yin H et al (2013) IL-33 promotes Staphylococcus aureus-infected wound healing in mice. Int Immunopharmacol 17:432–438CrossRefPubMed

57.

Yoo J et al (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202:541–549CrossRefPubMedPubMedCentral

58.

Zhao W, Hu Z (2010) The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol 7:260–262CrossRefPubMedPubMedCentral

Title: Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis
Authors: Sonia C. DaSilva-Arnold
Anita Thyagarajan
Leroy J. Seymour
Qiaofang Yi
Joshua R. Bradish
Mohammed Al-Hassani
Hongming Zhou
Nikolajs J. Perdue
Val Nemeth
Aleksandar Krbanjevic
Ana P. M. Serezani
Matthew R. Olson
Dan F. Spandau
Jeffrey B. Travers
Mark H. Kaplan
Matthew J. Turner
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 3/2018
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-018-1807-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Investigating the roles of regulatory T cells, mast cells and interleukin-9 in the control of skin inflammation by vitamin D

The stem cell factor-stimulated melanogenesis in human melanocytes can be abrogated by interrupting the phosphorylation of MSK1: evidence for involvement of the p38/MSK1/CREB/MITF axis

BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid

Evaluating the accuracy of microRNA27b and microRNA137 as biomarkers of activity and potential malignant transformation in oral lichen planus patients

Subcutaneous injection of multipotent mesenchymal stromal cells admixed with melanoma cells in mice favors tumor incidence and growth: a systematic review and meta-analysis

Construction of a plasmid vector containing epidermal growth factor receptor and C-Jun shRNA